Mergers and Acquisitions

Date: 2018-06-16

Type of information: Company acquisition

Acquired company: Interactive Biosoftware (Frane)

Acquiring company: Sophia Genetics (France - Switzerland)

Amount: undisclosed


  • • On June 16, 2018, Sophia Genetics, a global leader in data-driven medicine, announced at the European Human Genetics Conference (ESHG 2018) that it has completed the acquisition of French-based tech company Interactive Biosoftware (IBS), the creators of Alamut®, the most used decision support software for clinical genomic data interpretation. This software is currently deployed in over 450 hospitals and is highly complementary to Sophia Genetics' offering.


  • Interactive Biosoftware was founded in April 2007, in Rouen, by a group of medical and computer scientists focusing on practical software applications for health care and life sciences, particularly in the field of genomics.  The company's mission is to provide geneticists and clinical researchers with the most sophisticated, easy to use and reliable software to help them with their genomic analysis needs. It has acquired a strong reputation and the trust of experts worldwide thanks to the global adoption of Alamut®, the standardized decision support software for clinical genomic data interpretation.
  • This acquisition reinforces Sophia Genetics' commitment to continuously support hospitals and patients with powerful technologies. Interactive Biosoftware's expertise and teams will join Sophia Genetics' workforce. A seamless onboarding will ensure Alamut® users' experience.
  • Sophia Genetics has developed SOPHiA AI, the most advanced technology for clinical genomics, helping healthcare professionals better diagnose and treat patients. The global network of 480 institutions from 60 countries that use the SOPHiA DDM® analytical platform powered by the company forms the world's largest clinical genomics community. By enabling the rapid adoption of genomic testing worldwide, turning data into actionable clinical insights, and sharing knowledge through its community, Sophia Genetics is democratizing Data-Driven Medicine to save lives equally. The company's achievements were recognized by MIT Technology Review who ranked it amongst the 50 Smartest Companies in 2017.


Is general: Yes